Screener
Solid Biosciences Inc. SLDB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
FAQ
- What is Solid Biosciences Inc.'s cash & equivalents?
- Solid Biosciences Inc. (SLDB) reported cash & equivalents of $159.39M in Q2 2026.
- How has Solid Biosciences Inc.'s cash & equivalents changed year-over-year?
- Solid Biosciences Inc.'s cash & equivalents increased by 14.7% year-over-year, from $138.93M to $159.39M.
- What is the long-term trend for Solid Biosciences Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Solid Biosciences Inc.'s cash & equivalents has grown at a -17.3% compound annual growth rate (CAGR), from $154.74M to $59.9M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Solid Biosciences Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude